[The use of Neupogen in prevention of purulent septic complications after radical surgery for esophageal cancer].
To prevent purulent complications, a granulocyte-colony stimulating factor--filgrastim-neupogen (200 or 480 mg) was injected during radical surgery and for the following 6 weeks in 26 patients with esophageal tumors and gastric cancer disseminated to the esophagus. A significant rise in leukocyte levels which potentiated antibacterial therapy was recorded in all patients. Purulent septic complication was registered in one case.
Drukin
E Ia
EIa
Municipal Oncological Dispensary, St. Petersburg.
Manikhas
G M
GM
Pavlysh
A V
AV
D000328:Adult; D000368:Aged; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000601:surgery*; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013530:Surgical Wound Infection / Q000209:etiology / Q000276:immunology* / Q000517:prevention & control*; D016896:Treatment Outcome
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim